Analysis of Point Mutations in Clinical Samples of Urothelial Carcinoma

  • Mustafa Alamyar
  • Ellen C. ZwarthoffEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1655)


In the last two decades specific point mutations in oncogenes have been identified in urinary bladder cancers. Identification of these mutations in clinical samples (e.g., urine or tumor tissue) can be of use for diagnostic or prognostic purposes. In this chapter we describe how mutations in multiple oncogenes can be identified with a simple assay.

Key words

Oncogenic mutations FGFR3 TERT PIK3CA RAS DNA isolation Mutation analysis 


  1. 1.
    Kompier LC, Lurkin I, van der Aa M, van Rhijn BW et al (2010) FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 5:e13821CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    van Rhijn BW, Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F et al (2003) Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 21:1912–1921CrossRefPubMedGoogle Scholar
  3. 3.
    Allory Y, Beukers W, Sagrera A et al (2014) Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 65:360–366CrossRefPubMedGoogle Scholar
  4. 4.
    Hurst CD, Platt FM, Knowles MA (2014) Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. Eur Urol 65:367–369CrossRefPubMedGoogle Scholar
  5. 5.
    Zuiverloon TC, van der Aa MN, van der Kwast TH et al (2010) Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. Clin Cancer Res 16:3011–3018CrossRefPubMedGoogle Scholar
  6. 6.
    van Kessel KE, van Neste L, Lurkin I et al. (2016) Evaluation of an epigenetic profile for the detection of bladder cancer in patients with hematuria. J Urol 195:601-607CrossRefPubMedGoogle Scholar
  7. 7.
    van Kessel KE, Kompier LC, de Bekker-Grob EW, Zuiverloon TC et al (2013) FGFR3 mutation analysis in voided urine samples to decrease cystoscopies and cost in nonmuscle invasive bladder cancer surveillance: a comparison of 3 strategies. J Urol:1676–1681Google Scholar
  8. 8.
    Hurst CD, Zuiverloon TC, Hafner C et al (2009) A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene. BMC Res Notes 2:66CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2018

Authors and Affiliations

  1. 1.Department of PathologyErasmus MCRotterdamThe Netherlands

Personalised recommendations